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Chemical probes and drugs often bind to functional domains on disease-relevant proteins. A 7 
study suggests a chemical genetic approach to establish on-target effects by swapping the 8 
targeted domain, affords resistance to pharmacological inhibition while retaining 9 
functionality. 10 
 11 
Alessio Ciulli 12 
 13 
In target-driven discovery world, a founded paradigm of chemical intervention involves 14 
developing small molecules that bind individual domains to inhibit protein function. 15 
Understanding the true “on” and “off” target contributions to pharmacological activity is 16 
one of the pillars of target validation1, but can be difficult to realize when the protein in 17 
question shares homologous domains with other proteins. This is especially true of 18 
epigenetic protein families that mediate transcriptional signaling through the catalytic or 19 
scaffolding function of their structural domains2, many of which are difficult to target 20 
selectively with small molecules because of their conserved binding sites3. In this issue, 21 
Hohmann et al.4 describe an elegant approach that involves swapping the targeted 22 
domain with one from a structurally homologous family member that does not bind the 23 
probe, to confer probe resistance and validate the relevant cellular target. 24 
 25 
Epigenetic effectors are multi-domain proteins that catalyze installment, removal or 26 
recognition of posttranslational modifications of amino acids on histones amongst other 27 
substrates. Many epigenetic proteins function as part of large complexes that bind to 28 
promoters, enhancers and super-enhancer regions of the genome, remodeling chromatin 29 
and regulating transcription of genes that can sustain growth and proliferation of cancer 30 
cells5. Amongst these are thechromatin remodelers switch/sucrose non-fermentable 31 
(SWI/SNF), multisubunit enzymes that utilize the energy derived from ATP hydrolysis to 32 
open up chromatin and activate transcription6. Identifying the most relevant target 33 
protein in a given disease context is an important first step. 34 
 35 
 In the study by Hohmann et al. Brd9, which is a subunit of a mammalian SWI/SNF complex 36 
(also known as BAF)6, was found to be required for the growth of acute myeloid leukemia 37 
(AML) cells. Brd9 supports leukemic maintenance by sustaining Myc expression via its 38 
essential bromodomain - the reader domain of lysine acetylation. These observations 39 
provided convincing genetic rationale for chemical probe discovery effort, and 40 
nanomolar-potency inhibitors targeting the Brd9 bromodomain were developed by 41 
fragment-based drug design, achieving >1,000 fold selectivity against the main potential 42 
off-target bromodomain of the BET protein Brd47. Inhibitor treatment led to the release, 43 
albeit partial, of the entire BAF complex from chromatin, and phenocopied the cellular 44 
effect and transcriptional response of Brd9 knockdown (Fig. 1a). Crucially, an engineered 45 
Brd9 variant in which the bromodomain of Brd9 was substituted by the first bromodomain 46 
of Brd4 was devised. This “domain-swap” allele BRD9-BET proved insensitive to chemical 47 
inhibition by chemical probe BI-7273 but could substitute the wild-type function, 48 
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providing a powerful genetic tool to validate Brd9 as the relevant cellular target, and 49 
demonstrating the superior on-target effect of BI-7273 over other Brd9 probes4 (Fig. 1b). 50 
 51 
The most compelling finding of this study for chemical biology is the replacement of 52 
entire functional domains as a successful strategy to generate inhibitor-resistant alleles. 53 
This new approach extends on the use of naturally emerging or engineered drug-resistant 54 
mutations, which have proven of broad utility in the protein kinase space but have yet to 55 
be established with epigenetic targets. With success, chemical probes have been rendered 56 
exquisitely selective by chemical genetic approaches such as the “bump and hole”8, 57 
however for this to be generally applicable a pan-selective tool compound is required and 58 
single-point mutations have to be designed that do not significantly alter protein 59 
function, leaving the need for the mutant to be complemented by adequate synthetic 60 
modifications of the probe itself. The discovery that the BRD9-BET allele retained sufficient 61 
functionality in AML despite the evolutionary distance was unexpected, in part because it 62 
is known that bromodomains have different recognition specificities to histone peptides 63 
across the family2.  This observation suggests context- and loci- dependent specificities of 64 
chromatin occupancy of epigenetic proteins than might not be revealed using isolated 65 
domains and truncated histone peptides as substrates. The new findings bear also 66 
implications for targeting cancer epigenetics. The biological activities of the reported 67 
probes provide important benchmark for non-BET bromodomain inhibitors, which have 68 
previously proved unexceptional in cells. For example PFI-3, a chemical probe for the 69 
bromodomain of Brg1 (also known as Smarca4, another BAF subunit), failed to display 70 
anti-tumoral activity in cancer cells sensitive to Brg1 knockdown9. This highlights that 71 
distinct domain interactions may have different susceptibilities to pharmacological target 72 
modulation, despite being present within the same complex. 73 
 74 
How general could the domain-exchange approach be? The data presented4 on the 75 
methyltransferase EZH2, a prominent cancer target also found within a multiprotein 76 
histone-modifying complex6, and its SET domain-targeting probe GSK126, encourages 77 
optimism and a broadly applicable appeal, at least in the context of epigenetic domains. 78 
CRISPR-Cas9 screens are increasingly being developed to reveal cancer dependencies of 79 
epigenetic domains10, and it might be possible in many cases to identify paralogous 80 
domains that once swapped can be expressed in a functionally silent manner, without 81 
exhibiting dominant-negative effects on the endogenous protein. Ultimately, genetic 82 
engineering of homozygous domain swap knock-ins could surpass the need for 83 
transducing and selecting for exogenous alleles, not only improving target validation of 84 
existing probes but also opening new doors to the development of target-sensitive 85 
phenotypic screens in disease-relevant models. So switch domain, and validate your 86 
target! 87 
 88 
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Figure 1.  94 
Domain-swap to assess chemical probe on-target effects. (a) Probe binds to the target 95 
domain (BD, bromodomain), leading to pharmacological effect in cancer cells. (b) 96 
Swapping that target domain for one from a different protein that does not bind the 97 
probe leads to probe-resistant cells, establishing the probe’s on-target effects. In each 98 
case the remainder of the target protein remains unaltered (NTR, N-terminal region; CTR, 99 
C-terminal region). 100 
 101 
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